Interim Data Suggest Long-term Treatment with VYVGART Provides Improvement in Generalized Myasthenia Gravis Disease Scores
April 7, 2022
James F. Howard Jr., MD, professor in the ºÚÁÏÍø Department of Neurology, was principal investigator of the ADAPT+ trial for the experimental drug efgartigimod, developed by Belgian pharmaceutical company Argenx.